Pfizer Inc. $PFE Position Boosted by Focus Partners Wealth

Key Points

• Focus Partners Wealth has increased its stake in Pfizer to $38.07 million, owning over 1.5 million shares after a 14.5% increase in the first quarter.
• Analysts have adjusted price targets for Pfizer, with Morgan Stanley raising theirs to $33, while Berenberg Bank lowered theirs to $25, reflecting differing perspectives on the company's future.
• Pfizer reported better-than-expected quarterly earnings, with an EPS of $0.78 and a revenue of $14.65 billion, surpassing analyst expectations significantly.

Focus Partners Wealth boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 14.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,502,189 shares of the biopharmaceutical company's stock after acquiring an additional 190,288 shares during the period. Focus Partners Wealth's holdings in Pfizer were worth $38,066,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in PFE. William B. Walkup & Associates Inc. raised its holdings in shares of Pfizer by 1.2% during the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock worth $1,044,000 after purchasing an additional 454 shares during the period. Members Trust Co raised its holdings in shares of Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after purchasing an additional 467 shares during the period. Sutton Place Investors LLC raised its holdings in shares of Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock worth $224,000 after purchasing an additional 472 shares during the period. MSH Capital Advisors LLC raised its holdings in shares of Pfizer by 1.4% during the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company's stock worth $876,000 after purchasing an additional 485 shares during the period. Finally, Signature Estate & Investment Advisors LLC raised its holdings in shares of Pfizer by 2.6% during the first quarter. Signature Estate & Investment Advisors LLC now owns 19,254 shares of the biopharmaceutical company's stock worth $488,000 after purchasing an additional 486 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research reports. Berenberg Bank dropped their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Morgan Stanley increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Bank of America increased their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Jefferies Financial Group increased their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Finally, Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $28.12.

Pfizer Price Performance

PFE traded down $0.95 on Friday, reaching $23.91. The company had a trading volume of 81,158,118 shares, compared to its average volume of 34,996,196. The company has a fifty day moving average of $24.79 and a 200-day moving average of $24.30. The company has a market capitalization of $135.94 billion, a P/E ratio of 12.72, a PEG ratio of 0.88 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.